{
  "url": "https://struct.news/briefs/cg-oncology-booked-12m-of-revenue-as-clinical-costs-drove-a-791m-loss",
  "title": "CG Oncology booked $1.2M of revenue as clinical costs drove a $79.1M loss",
  "summary": "R&D climbed to $54.7M, including a $21.3M increase in external clinical-trial costs tied to CMC work.",
  "published_at": "2026-08-06T12:53:18.295083+00:00",
  "publisher": "Struct",
  "usage": "Figures are as reported by the company. Quote with attribution to the source filing.",
  "company": {
    "name": "CG Oncology, Inc.",
    "ticker": "CGON",
    "cik": "1193125",
    "sector": "Healthcare",
    "industry": "Biotechnology"
  },
  "source_filing": {
    "form": "10-Q",
    "filed": "2026-08-06",
    "accession": "0001193125-26-336918",
    "url": "https://www.sec.gov/Archives/edgar/data/1991792/000119312526336918/ck0001991792-20260630.htm"
  },
  "comparison_filing": {
    "form": "10-Q",
    "filed": "2025-08-08",
    "url": "https://www.sec.gov/Archives/edgar/data/1991792/000095017025105855/ck0001991792-20250630.htm"
  },
  "reported_figures": [
    {
      "group": "The filing in three numbers",
      "label": "Revenue",
      "value": 4040000,
      "display": "$4.0M",
      "unit": "usd",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "sec_filing",
        "label": "Filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-336918",
        "filing_date": "2026-08-06"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Revenue YoY",
      "value": 254.6971027216857,
      "display": "+254.7%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-336918",
        "filing_date": "2026-08-06"
      }
    },
    {
      "group": "The filing in three numbers",
      "label": "Operating margin",
      "value": -4722.1287128712875,
      "display": "-4722.1%",
      "unit": "percent",
      "period": "2025-12-31",
      "detail": null,
      "source": {
        "kind": "jodie_calculation",
        "label": "Calculated from filed company results",
        "form": "10-Q",
        "accession": "0001193125-26-336918",
        "filing_date": "2026-08-06"
      }
    }
  ],
  "watch_next": [
    {
      "type": "product_pipeline",
      "statement": "External clinical-trial expenses rose materially in the latest three months, primarily because of higher CMC costs and increased headcount.",
      "importance": "medium",
      "evidence": "The increase of $23.3 million in R&D expenses for the three months ended June 30, 2026 was primarily due to an increase of $21.3 million in external clinical trial expenses related to higher Chemistry, Manufacturing, and Controls (CMC) costs",
      "source_date": "2026-08-06"
    }
  ],
  "related_tickers": [
    "CGON"
  ],
  "disclaimer": "Descriptive reporting of filed results. Not investment advice, and contains no forecast or recommendation."
}